(Health Korea News / Lee Chang-yong) Jeil Pharmaceutical and Dong-A ST have joined hands as joint sales partners for the 37th domestic P-CAB new drug, ‘Jakyubojeong.’
On the 5th, Onconic Therapeutics selected Jeil Pharmaceutical and Dong-A ST as partners for domestic sales and marketing of ‘Jakyubojeong’ and signed a joint sales agreement.
‘Jakyubojeong’ is a new next-generation P-CAB (potassium-competitive acid suppressant) drug developed by Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical. It is expected to replace existing PPI (proton pump inhibitor) drugs in the market for peptic ulcer treatments such as gastroesophageal reflux disease.
This is the first time that Jeil Pharmaceutical and Dong-A ST have formed a partnership. Under this agreement, the two companies will jointly conduct sales and marketing activities for ‘Jakyubojeong’ targeting all hospitals and clinics in Korea.
Dong-A ST owns many blockbuster digestive medicine products such as ‘Motilitone’, ‘Gaster’, and ‘Styrene’, and has extensive experience in launching and distributing new digestive medicines.
Jeil Pharmaceutical has a long history of success in the field of digestive diseases, backed by strong sales and marketing capabilities, and expects that synergy will be maximized through this partnership with Dong-A ST.
Jeil Pharmaceutical plans to solidify its strategic partnership with Dong-A ST to enhance its competitiveness and accelerate the market entry of ‘Jakyubojeong’.
The jointly sold item, ‘Jakyubojeong’, was approved as the 37th new drug in Korea in April. ‘Jakyubojeong’ has dramatically improved the shortcomings of existing PPI drugs, such as slow onset of action, short half-life, dietary influence, and drug interaction problems. While PPI drugs take 4-5 days to reach maximum effect, ‘Jakyubojeong’ takes effect immediately after taking it and is more effective in relieving nocturnal heartburn symptoms due to its long half-life. Since it does not need to be activated by acid, it can be taken regardless of meals, greatly improving patient convenience.
According to pharmaceutical statistics, Ubis, the total sales of P-CAB and PPI preparations last year amounted to KRW 912.7 billion. Of this, P-CAB accounted for 23.8% (KRW 217.6 billion). The market share of P-CAB has steadily increased from 4.0% in the first half of 2019, the first year of its launch, to 27.1% in the first half of 2024.
Jeil Pharmaceutical plans to lead the overall growth of the company along with the P-CAB market, which will continue to grow based on this partnership. Onconic Therapeutics plans to accelerate R&D to expand the indications of ‘Jakubojeong’ beyond the existing approved erosive esophageal reflux disease, including gastric ulcer and NSAID-induced peptic ulcer prevention, and successfully expand the new drug to the market.
Seong Seok-je, CEO of Jeil Pharmaceutical, said, “I hope that this collaboration will establish itself as a successful collaboration case in the industry and become an important stepping stone for ‘Jakyubojeong’ to become a blockbuster new drug,” and added, “We will continue to do our best to ensure that ‘Jakyubojeong’ can be an effective treatment method for patients with gastroesophageal reflux disease based on its excellent efficacy and safety.”
Dong-A ST CEO Jeong Jae-hoon said, “‘Jakyubojeong’ is an innovative new drug that overcomes the limitations of existing treatments and will become a new treatment option for patients,” adding, “We will do our best to widely publicize the excellence of ‘Jakyubojeong’ and expand market share through close cooperation between our two companies in the future.”
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
